Home
Contact Us
Sitemap
AccessibilityGaviscon Info - Prescribing
GAVISCON ADVANCE COMBINED PRESCRIBING INFORMATION
GAVISCON ADVANCE ANISEED SUSPENSION
and
GAVISCON ADVANCE PEPPERMINT FLAVOUR
| Active Ingredients: | Sodium alginate 1000mg and Potassium bicarbonate 200mg per 10ml dose. Also contains methyl and propyl hydroxybenzoates. |
| Indications: | Gaviscon Advance Aniseed Suspension Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn, indigestion occurring due to the reflux of stomach contents, for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. Can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy. Gaviscon Advance Peppermint Flavour Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals, or during pregnancy, or in patients with symptoms related to reflux oesophagitis. |
| Dosage Instructions: | Adults and children 12 years and over: 5-10 ml after meals and at bedtime. Children under 12 years: Should be given only on medical advice. |
| Contraindications: | Hypersensitivity to the active substances or to any of the excipients, including the esters of hydroxybenzoates (parabens). |
| Precautions and Warnings: | Each 10 ml dose has a sodium content of 106 mg (4.6 mmol) and a potassium content of 78 mg (2.0 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs which can increase plasma potassium levels. Each 10 ml contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. These medicinal products contain Methyl hydroxybenzoate and Propyl hydroxybenzoate, which may cause allergic reactions (possibly delayed). There is a possibility of reduced efficacy in patients with very low levels of gastric acid. If symptoms do not improve after seven days, the clinical situation should be reviewed. Treatment of children younger than 12 years of age is not generally recommended, except on medical advice. |
| Side-Effects: | Very rarely (<1/10,000) patients sensitive to the ingredients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions. |
| Basic NHS Price: | 250ml £2.70; 500 ml £5.40. |
| Marketing Authorisation: | PL 00063/0108 - Gaviscon Advance Aniseed Suspension PL 00063/0103 - Gaviscon Advance Peppermint Flavour |
| Supply Classification: | GSL, through registered pharmacies only. |
| Holder of Marketing Authorisation: | Reckitt Benckiser Healthcare (UK) Limited, Dansom Lane, Hull, HU8 7DS. |
| Date of Preparation: | November 2007 |
Gaviscon, Gaviscon Advance and the sword and circle symbol are trademarks.
GAVISCON ADVANCE TABLETS PRESCRIBING INFORMATION
| Active Ingredients: | Each tablet contains sodium alginate 500 mg and potassium bicarbonate 100 mg. |
| Indications: | Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn, indigestion occurring due to the reflux of stomach contents, for instance after gastric surgery, as a result of hiatus hernia, during pregnancy or accompanying reflux oesophagitis. |
| Dosage Instructions: | Adults and children 12 years and over: One to two tablets after meals and at bedtime. Children under 12 years: Should be given only on medical advice. Elderly: No dose modifications necessary for this age group. |
| Contraindications: | Hypersensitivity to any of the ingredients. |
| Precautions and Warnings: |
The sodium content of a two-tablet dose is 103 mg (4.5 mmol) and a potassium content of 78 mg (2.0 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs that can increase plasma potassium levels.
Each two-tablet dose contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. Due to its aspartame content this product should not be given to patients with phenylketonuria. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. If symptoms do not improve after seven days, the clinical situation should be reviewed. Treatment of children younger than 12 years of age is not generally recommended, except on medical advice. |
| Side-Effects: | Very rarely (<1/10,000), patients sensitive to the ingredients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions. |
| Retail Price: | £3.24 (60 tablets) |
| Marketing Authorisation: | PL 00063/0144. |
| Supply Classification: | GSL, through registered pharmacies only. |
| Holder of Marketing Authorisation: | Reckitt Benckiser Healthcare (UK) Limited, Dansom Lane, Hull, HU8 7DS. |
| Date of Preparation: | March 2005. |
| Active Ingredients: | Sodium alginate Ph Eur 500 mg, sodium bicarbonate Ph Eur 267 mg and calcium carbonate Ph Eur 160 mg per 10 mL dose. Also contains methyl and propyl hydroxybenzoates and sodium saccharin. |
| Indications: | Gastric reflux, reflux oesophagitis, heartburn, hiatus hernia, flatulence associated with gastric reflux, heartburn of pregnancy, and all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux. |
| Dosage Instructions: | Adults and children over 12: 10–20 mL after meals and at bedtime. Children 6 to 12 years: 5–10 mL after meals and at bedtime. Children 2 to 6 years: Should only be given on medical advice. Dose: 5–10 mL after meals and at bedtime. Children under 2 years: Not recommended. |
| Contraindications: | None known. |
| Precautions and Warnings: | Each 10 mL dose contains 6.2 mmol (141 mg) sodium. |
| Side-Effects: | Very rare hypersensitivity reactions. |
| RSP: | 150 mL £3.29; 300 mL £5.49; 600 mL £8.99 |
| Marketing Authorisation: | 0063/0031 - Liquid Gaviscon; 0063/0032 - Liquid Gaviscon peppermint flavour. |
| Supply Classification: | Through registered pharmacies only. |
| Holder of Marketing Authorisation: | Reckitt & Colman Products Limited, Dansom Lane, Hull, HU8 7DS. |
| Date of Preparation: | February 2001 |
GAVISCON INFANT PRESCRIBING INFORMATION
| Active Ingredients: | Sodium alginate 225 mg and magnesium alginate 87.5 mg per unit dose. |
| Indications: | Gastric regurgitation, gastro-oesophageal reflux and reflux associated with hiatus hernia in infants and young children. |
| Dosage Instructions: | Mix immediately before use. Do not give more than six times in 24 hours. Breast-fed infants: Under 10 lb (4.5 kg), one dose. Over 10 lb (4.5 kg), two doses. Add one teaspoon (5 mL) of cooled, boiled water to the powder in a glass, mix to a smooth paste, add two more teaspoons of the water and mix. Give after each feed using a spoon or feeding bottle. Bottle-fed infants: Under 10 lb (4.5 kg), one dose to be mixed into not less than 4 fluid oz (115 mL) of each feed in the bottle and shaken well. Over 10 lb (4.5 kg), two doses to be mixed into not less than 8 fluid oz (225 mL) of each feed in the bottle and shaken well. Young children: Two doses, prepared as for breast-fed infants, to be drunk after each meal. |
| Contraindications: | Intestinal obstruction, established diarrhoea, gastro- enteritis or situations where excessive water loss is likely. Known or suspected impairment of renal function since each dose contains 0.92 mmol of sodium and may add to the risk of hypernatraemia. Not to be used in premature infants or infants under one year unless under medical supervision. |
| Precautions and Warnings: | Dosage instructions must be followed to avoid an excessive amount of product per feed and the possible risk of hypernatraemia. A medical review of the patient’s condition should be undertaken seven days after initiating treatment or before if symptoms worsen. Not to be used with thickening agents or infant milk preparations containing a thickening agent. |
| Side-Effects: | An excessive concentration of product may lead to gastric distension. |
| Retail Price: | 15 dual sachets £2.46. |
| Marketing Authorisation: | 0063/0099. |
| Supply Classification: | Pharmacy Medicinal Product. |
| Holder of Marketing Authorisation: | Reckitt & Colman Products Limited, Dansom Lane, Hull, HU8 7DS. |
| Date of Preparation: | February 2001 |
Gaviscon, Gaviscon Advance, Gaviscon Liquid, Gaviscon Infant, and the Sword and Circle symbol are trademarks.
